EDINBURGH, UK — 14 September 2017
Global biotherapeutics leader CSL Behring today announced that its “Join Together” campaign at the 2017 European Society for Immunodeficiencies (ESID) meeting has resulted in a rel="noopener noreferrer" €15,000 donation to IPOPI, the International Patient Organisation for Primary Immunodeficiencies.
Visitors to CSL Behring’s booth at the ESID exhibition were invited to log their home location on a digital world map. The 4-day conference hosted over 1,600 attendees from 20 countries who, like CSL Behring, are committed to raising awareness of immunodeficiencies.
“As a long-standing partner with IPOPI, CSL Behring is pleased and proud to support patients with this donation,” said Karen MacPhail, Senior Director, Immunology, CSL Behring. “IPOPI’s efforts to raise awareness of immunodeficiencies and improve access aligns closely with our dedication to patient focus.”
“IPOPI relies on donations in fulfilling its commitment to advocate for PID patients around the world,” said Johan Prevot, Executive Director of IPOPI. “CSL Behring’s ongoing support helps enable us to provide programs to improve awareness and care of PID, promote access to treatment and the importance of early diagnosis. We are grateful to all our industry partners who provide, among other resources, donations like this.”
About the international Patient Organisation for Primary Immunodeficiencies
The International Patient Organisation for Primary Immunodeficiencies (IPOPI), is the association of national patient organisations dedicated to improving awareness, access to early diagnosis and optimal treatments for primary immunodeficiency (PID) patients worldwide. Established in 1992, IPOPI works as the global advocate for the PID patient community in cooperation with its National Member Organisations (NMOs) and rel="noopener noreferrer" key PID stakeholders. For more information rel="noopener noreferrer" visit www.ipopi.org rel="noopener noreferrer" and www.ipic2017.com rel="noopener noreferrer" and follow on twitter.com/ipopi_info and www.facebook.com/ipopipid.
About CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent rel="noopener noreferrer" hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs nearly 20,000 people, rel="noopener noreferrer" delivering its life-saving therapies to people in more than 60 countries. For more information visit www.CSLBehring.com and follow us on www.Twitter.com/CSLBehring.
Office: +1 610 878 4802
Mobile: +1 610 306 9355